As more emerging biopharma companies, novel active substances, biosimilars and generics enter the market and higher investment is made in R&D for new drugs, tech can transform patient support programs to ensure market differentiation.In this Drug Channels article, Chief Commercial Officer Edward Hensley offers his insights on the five ways...